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Abstract 27 
Study question 28 
What is the impact of different age and BMI groups on total investigation and treatment costs in 29 
women attending a secondary/tertiary care fertility clinic? 30 
  31 
Summary answer 32 
Women in their early to mid-30s and women with normal BMI had higher cumulative investigation 33 
and treatment costs, but also higher probability of live birth.  34 
 35 
What is known already? 36 
Female age and BMI have been used as criteria for rationing publically funded fertility treatments. 37 
Population based data on the costs of investigating and treating infertility are lacking. 38 
 39 
Study design, size and duration 40 
A retrospective cohort study of 2463 women was conducted in a single secondary/tertiary care fertility 41 
clinic in Aberdeen, Scotland from 1998-2008.   42 
 43 
Participants/materials, setting, methods: 44 
Participants included all women living in a defined geographical area referred from primary care to a 45 
specialised fertility clinic over an 11 year period. Women were followed up for 5 years or until live 46 
birth if this occurred sooner. Mean discounted cumulative National Health Service costs (expressed in 47 
2010/2011 GBP) of fertility investigations, treatments (including all types of assisted reproduction)  48 
and pregnancy (including delivery episode) and neonatal admissions were calculated and summarised 49 
by age (≤30, 31-35, 36-40, >40 years) and BMI groupings (<18.50, 18.50-24.99 (normal BMI), 25.00-50 
29.99, 30.34.99, ≥35.00 kg/m2). Further multivariate modelling was carried out to estimate the impact 51 
of age and BMI on investigation and treatment costs and live birth outcome, adjusting for covariates 52 
predictive of the treatment pathway and live birth. 53 
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 54 
Main results and the role of chance 55 
Of the 2463 women referred, 1258 (51.1%) had a live birth within 5 years, with 694 (55.1%) of these 56 
being natural conceptions. The live birth rate was highest among women in the youngest age group 57 
(64.3%), and lowest in those aged >40 years (13.4%). Overall live birth rates were generally lower in 58 
women with BMI >30 kg/m2. The total costs of investigations were generally highest among women 59 
younger than 30 years (£491 in those with normal BMI), whilst treatment costs tended to be higher in 60 
31-35 year olds (£1,840 in those with normal BMI).  Multivariate modelling predicted a cost increase 61 
associated with treatment which was highest among women in the lowest BMI group (across all ages), 62 
and also highest among women aged 31-35 years. The increase in the predicted probability of live 63 
birth with exposure to treatment was consistent across age and BMI categories (~10%), except in the 64 
oldest age group where a slightly smaller increase in the probability of live birth was observed. The 65 
ratio of increased costs to the increased probability of live birth in women who were treated increased 66 
markedly in women over the age of 40 years, but tended to fall as BMI increased within all age groups.  67 
 68 
Limitations and reason for caution 69 
Our results, based on retrospective observational data from a single centre, have limited 70 
generalizability and are not free from clinician and clinic selection bias which can influence the choice 71 
of treatments as well as their costs. 72 
 73 
Wider implications of the findings 74 
Spontaneous live birth rates were particularly high in younger women with unexplained infertility, 75 
suggesting that expectant management is a reasonable option in this group.  The policy of not over-76 
investigating older women and offering early treatment where appropriate still incurred the highest 77 
costs per additional live birth associated with treatment, owing to the lower probability of treatment 78 
success. The increased additional cost for each live birth associated with treatment for women with 79 
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decreasing BMI across all age groups, suggests that it may be possible to identify a more targeted 80 
approach to treatment.   81 
 82 
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Introduction 89 
Considerations of cost-effectiveness are increasingly influential in informing treatment decisions 90 
within the National Health Service (NHS) in the UK as well as in other health care settings across the 91 
world.  Results of published studies showing that women who are older and heavier are less likely to 92 
achieve a pregnancy has led to rationing of access to publicly funded fertility treatment on the basis 93 
of age and BMI (National Collaborating Centre for Women's and Children's Health 2013).  In addition, 94 
pregnant women who are obese have been shown to have a higher risk of fetal anomalies (Stothard 95 
et al 2009), operative deliveries (Poobalan et al 2009) and pregnancy complications, such as diabetes 96 
and hypertension (Cedergren 2004, Bhattacharya et al 2007), all of which  can increase the cost of 97 
perinatal care (Denison et al 2014). Whilst a substantial amount of data have been published on the 98 
costs of IVF (National Collaborating Centre for Women's and Children's Health 2013), the literature 99 
contains very little on the cumulative costs of all fertility treatments and investigations (including IVF). 100 
There are also few studies which have been able to describe the cost of treatment independent and 101 
treatment dependent pregnancies and live births in couples with fertility problems. In the UK, the 102 
National Institute for Health and Care Excellence (NICE 2013), which has generated cost-effectiveness 103 
models to determine the criteria required for access to NHS funded IVF treatment, acknowledges the 104 
paucity of data in this field.  A Dutch group used data from the literature to inform models on the 105 
cumulative costs and outcomes of ovulation induction, intrauterine insemination (IUI) and IVF with 106 
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respect to overweight and obese women (Koning et al 2010). However, to our knowledge, no previous 107 
study has used population based data to estimate the actual impact of current practice on the 108 
cumulative costs of both fertility investigations and treatment on women in different age and BMI 109 
categories.  The aim of this study was to estimate the mean total health service costs of investigating 110 
and treating women with infertility living within a defined geographical area. 111 
 112 
 113 
Methods 114 
Following approval from the North of Scotland Research Ethics Committee (10/S0802/57) and the 115 
relevant Caldicott Guardians, fertility and maternity data were obtained on all women residing in the 116 
Aberdeen City District who attended the Aberdeen Fertility Centre (AFC) for the first time between 117 
1998 and 2008. These two data sources were linked using unique identifiers.     118 
 119 
The AFC is ideally placed to carry out such a study since it holds extensive electronic fertility and 120 
maternity records for all women in Aberdeen City district and has logged all fertility investigation and 121 
treatment events since 1991. Assessments and tests were performed according to evidence-based 122 
standard operating procedures of the AFC based on the NICE guidelines of management of infertility 123 
in the UK or, prior to this, Royal College Guidelines (Royal College of Obstetricians and Gynaecologists, 124 
1998).  Details of the clinical protocols used in decision making at the AFC are included in the 125 
Supplementary Data.  The Aberdeen Assisted Reproduction Unit Database (ARUD) holds details on all 126 
IVF events since 1998, and the Aberdeen Maternity and Neonatal Databank (AMND) has information 127 
on all pregnancies and deliveries occurring in Aberdeen City and district since 1950 128 
(http://www.abdn.ac.uk/amnd/). These databases have been used previously to assess the cost of IVF 129 
treatment in women in different age and BMI categories (Maheshwari et al 2009, 2010).  In this study 130 
we used them to assess the costs and outcomes of all fertility investigations and treatments in a cohort 131 
of women referred from primary care to a specialised clinic.  132 
 133 
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Data were extracted on all women for a 5 year period or until the first live birth - if this occurred sooner 134 
- after an initial visit to the AFC. A 5 year period was chosen in order to factor in any waiting time 135 
between treatments and minimise loss to follow up. The AFC database provided baseline 136 
characteristics, outcomes of diagnostic tests, infertility diagnosis, and details of clomiphene citrate, 137 
gonadotrophin and intrauterine insemination (IUI) treatments. Details of IVF treatment were obtained 138 
from the ARUD.  Data on on-going pregnancies, antenatal care, obstetric care and neonatal care were 139 
obtained from the AMND. The data were linked and anonymized by the University of Aberdeen data 140 
management team, using date of first attendance at the AFC clinic, date of birth, unit number, CHI 141 
(unique identification) number and partner’s date of birth.  142 
 143 
Inclusion criteria 144 
All women residing in Aberdeen City district (identified by their post codes) and attending AFC for the 145 
first time between 1998 and 2008 were eligible for inclusion.  Those living outside Aberdeen City 146 
District were excluded as some of their maternity records were not recorded within the AMND.  147 
 148 
Outcomes 149 
Our outcome measure, live birth, was considered to be treatment dependent if the antenatal booking 150 
date for the pregnancy was within 3 months of a treatment cycle reporting an outcome consistent 151 
with pregnancy. A live birth was considered to be treatment independent if there was no preceding 152 
treatment cycle or if the timing and/or reported outcome of the preceding treatment cycle was 153 
inconsistent with the recorded booking date for the live birth. As AFC is the only fertility centre in 154 
Aberdeen, all pregnancies in women who had no contact with AFC were deemed (in the absence of 155 
any further information) to be treatment independent (Thompson et al 2005).  156 
 157 
Power Calculation 158 
Approximately 500 new couples from Aberdeen and its surrounding areas are seen in the AFC each 159 
year.  As 50% of them are expected to be resident in Aberdeen City District, we anticipated a sample 160 
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size of approximately 2500 new couples over the study period. Assuming that the proportions of 161 
women in each BMI category were similar to those reported by our group in a previous study 162 
(Maheshwari et al, 2009), it was estimated that a sample of 2500 women would have more than 90% 163 
power to detect a difference in costs of one third of a standard deviation between the obese group 164 
(BMI >=30kg/m2) and the normal BMI group (18.5-24.9kg/m2). 165 
 166 
Resource use and costs 167 
Costs to the health service were estimated using a combination of top-down (aggregated high level) 168 
and bottom-up (detailed micro-costing) approaches. Estimates of resource use inputs required for 169 
investigations and treatments were based on a combination of patient records (for certain quantities 170 
of consumable items), centre treatment and monitoring protocols, and the opinion of AFC clinicians. 171 
Resource items considered included staff time, consumables, capital equipment, overheads and 172 
space.  173 
 174 
The unit costs to add to the resource use data were obtained from Aberdeen Assisted Reproduction 175 
Unit expenditure records for consumables.  Staff time was valued using nationally available unit costs 176 
(per hour) incorporating gross salaries, employer superannuation and national insurance 177 
contributions, allocated overheads, and costs associated with the use of building space (Curtis 2011). 178 
These incorporate the annuitized cost of the resources invested in training health professionals (Curtis 179 
2011).   180 
 181 
For capital equipment, an equivalent annual cost was calculated based on the purchase price and 182 
expected serviceable life span of each item, and this in turn was used to calculate an average cost per 183 
use based on estimated annual throughput. A discount rate of 3.5% was applied to capture the 184 
opportunity cost of investing in capital equipment.  Discounting is performed in economic analyses to 185 
account for societal time preference so as to determine the net present value of costs in a common 186 
base year.  Where use of space associated with a procedure was missing from the staff cost ready 187 
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reckoner, this was estimated using a unit cost per square metre for a new build, multiplied by the area 188 
of space used and annuitized over a 25 year period. Costs calculated are presented in Supplementary 189 
tables 1-6. 190 
 191 
For early treatment outcomes (biochemical pregnancy, ectopic pregnancy and miscarriage) the 192 
average unit costs of diagnosing and treating these events, as reported by Maheshwari et al (2010), 193 
were inflated to 2010/2011 values (Supplementary table 3). Antenatal care contacts, including clinic 194 
appointments, scans, blood tests, and hospital admissions were valued using readily available (top-195 
down) unit costs based on financial returns data, as were neonatal admissions (ISD Scotland,  196 
http://www.isdscotland.org/Health-Topics/Finance/Costs/File-Listings-2011.asp) (Supplementary 197 
table 6).  198 
 199 
All the costs were expressed in 2010/2011 GBP and future costs (beyond year 1) were discounted at 200 
a rate of 3.5% per annum in line with HM Treasury recommendations and NICE (2013). Total costs 201 
were estimated for each individual by multiplying the numbers of different procedures reported by 202 
the estimated unit cost for each procedure, and then summing across all procedures.  203 
 204 
Statistical Methods 205 
Analyses were conducted using SPSS (version 18), STATA (version 12) and SAS (version 9.3).   206 
Characteristics of the women attending the fertility centre and treatments undertaken are reported 207 
by BMI group and for women whose BMI was missing.  Comparison of baseline characteristics and 208 
treatments undertaken across BMI groups (<18.5kg/m2, 18.5-24.9kg/m2, 25-29.9kg/m2, 30-209 
34.9kg/m2 and >=35 kg/m2) were made.  Pearson’s chi-squared test was used to test for an 210 
association between BMI group and each of the following variables: causes of infertility, the 211 
proportion of nulliparous women, smoking status, alcohol status, and each type of fertility treatment.  212 
The mean female age was compared between the BMI groups using analysis of variance, and the 213 
Kruskall Wallis test was used to compare duration of infertility between the BMI groups. The 214 
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proportion of missing data was documented and the characteristics of, and treatments given to, 215 
patients with complete data were compared to patients with missing data using similar tests as above. 216 
Clinical outcomes, mean discounted investigation costs, mean discounted treatment costs, mean 217 
discounted pregnancy, delivery and neonatal costs, number of women treated and the mean (SD) 218 
number of treatment cycles were presented by BMI and age groups (≤30 years, 31 to 35 years, 36 to 219 
40 years, >40 years).  220 
 221 
The impact of age and BMI on total fertility investigation and treatment costs and live birth was 222 
assessed using general linear regression.   Pregnancy, delivery and neonatal costs were not included 223 
in this part of the analysis.  These models were adjusted for exposure to fertility treatment (yes/no), 224 
primary versus secondary infertility, duration of infertility, year of registration and cause of infertility 225 
(including male factor, endometriosis, ovulatory, unexplained, tubal and other).  With the exception 226 
of duration of infertility and year of registration, which were entered as covariates (i.e. linear effects), 227 
all predictors were fitted as factors (i.e. categorical effects).  Interactions between the fertility 228 
treatment indicator and BMI category, and between the treatment indicator and age category, were 229 
also included in the model.  A significant age (or BMI) treatment interaction would suggest that the 230 
effect of BMI (or age) category on cost/live birth differs between women who did and did not have 231 
treatment. Since they help to explain further variation, any significant interactions remained in the 232 
model.  These models were used to predict costs and the probability of live birth by age and BMI 233 
groupings, with and without exposure to treatment. In this calculation, the results are expressed for 234 
a cohort of patients with unexplained infertility - a group where spontaneous or treatment 235 
independent pregnancies are more common than in other groups – with all other predictors held fixed 236 
at either their reference category or mean value.  237 
 238 
The 95% confidence intervals for the predicted probabilities and costs were calculated by drawing 239 
3000 random bootstrap samples from the dataset.  For each bootstrapped sample we fitted the 240 
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models predicting cost and live birth, calculated the predicted costs and probabilities of live birth, and 241 
took the values at the 2.5th and 97.5th percentile as the lower and upper confidence limit respectively. 242 
 243 
The above analysis was conducted using only patients with complete data.  A multiple imputation 244 
process was performed to impute values for all predictors with missing information.   This was 245 
performed using a combination of the Monte Carlo Markov Chain method and predicted mean 246 
matching regression (Rubin, 1987). Many other variables, aside from those used in the statistical 247 
modelling, were used to inform the imputation process.  These included alcohol status, smoking 248 
status, parity, and number of cycles of different fertility treatments i.e. clomiphene citrate, 249 
gonadotrophin, IUI, donor insemination, fresh IVF and frozen IVF.  The statistical analysis described 250 
above was performed for the imputed database. 251 
 252 
Results 253 
Patient and treatment characteristics 254 
A total of 2463 women from the Aberdeen City District attended the fertility clinic at the AFC for the 255 
first time between 1998 and 2008.  Of 1736 (70.5%) women whose BMI data were available, 56% had 256 
a normal BMI (i.e. 18.5-24.9kg/m2), 25% were overweight (i.e. 25-29.9kg/m2) and 16% were obese 257 
(≥30 kg/m2). Table 1 shows the baseline characteristics of women in different BMI categories along 258 
with the treatments received. Women with a BMI <18.5 kg/m2 were significantly younger than women 259 
with BMI in the normal range and women with BMI between 30 to 34.9 kg/m2. Over half of all women 260 
with BMI ≥ 35 kg/m2 presented with anovulatory infertility whilst more women (36%) in the normal 261 
BMI group had unexplained infertility. Fewer women with BMI over 35 kg/m2 underwent IVF/ICSI 262 
treatment as compared to women with lower BMIs. Women with missing BMI data were significantly 263 
older (33 versus 32 years of age), had more secondary infertility (55% versus 41%), smoked more (27% 264 
versus 22%) and had a  higher percentage of tubal factor infertility (26% versus 17%) compared to 265 
women with complete data (Supplementary Table 7). A significantly lower proportion had anovulatory 266 
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(14% versus 23%) and unexplained (24% versus 31%) infertility.  They also had less clomifene citrate 267 
(14% versus 21%), gonadotrophin (1% versus 3%), and IVF (29% versus 34%) treatment. 268 
  269 
Live birth outcome 270 
Of all the women referred to AFC from primary care with a diagnosis of infertility during the study 271 
period, 1258 (51.1%) had a live birth within 5 years with 694 (55.1%) of these being treatment 272 
independent (spontaneous) conceptions. In those ≤30 years of age, 36.7% conceived spontaneously, 273 
compared to only 9.1% of women over the age of 40 years.  Out of the 1211 (49.2%) women who 274 
received any treatment, 564 (46.6%) had a treatment dependent live birth while 164 (13.5%) had a 275 
subsequent spontaneous live birth.  Out of the 1252 (50.8%) women who did not receive fertility 276 
treatment, 530 (42.3%) had a spontaneous live birth (Table 2).  In women of all age groups, 277 
spontaneous conception rates were higher than those as a direct result of active treatment, but were 278 
not associated with BMI (Table 2). 279 
 280 
Costs of investigation, treatment and pregnancy 281 
Table 3 highlights the mean investigation, fertility treatment and pregnancy costs by age and BMI 282 
group. Generally, the average cost of investigations tended to decrease with age and also tended to 283 
be lower in women classified as severely obese (≥35kg/m2). The average treatment costs generally 284 
appeared highest in women with normal BMI, except in the youngest age group. Average pregnancy 285 
and neonatal costs followed a similar pattern (reflecting the higher live birth rate in women with 286 
normal BMI) but in some age groups these costs were highest among women with BMI >35 kg/m2. 287 
The total costs of investigation and treatment were highest among women who were 30 years or 288 
younger, with BMI less than 25kg/m2.  289 
 290 
Table 4 shows the number of women in different age and BMI groups who were investigated, along 291 
with the resulting costs. In comparison with younger women with normal BMI, fewer women who 292 
were older (> 40 years) or heavier (BMI >30kg/m2) underwent a laparoscopy, possibly due to concern 293 
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about increased surgical and anaesthetic risks.  Cheaper investigations, such as blood tests (e.g. mid-294 
luteal progesterone and other hormonal tests), were more frequent in the obese group up to the age 295 
of 40 years.  With regards to fertility treatment (Table 5), fewer women in the older (and also the 296 
youngest) age groups, and in the higher BMI groups, received IVF treatment. By contrast, more women 297 
in the youngest age group (and within some age groupings the higher BMI groups) received treatment 298 
with clomifene citrate. 299 
 300 
Relationship between costs and age and BMI groups 301 
To further explore the relationship between costs of fertility investigation and treatment with age and 302 
BMI, we estimated these costs whilst adjusting for factors associated with the treatment pathway and 303 
treatment success. The modelling information (including the parameter estimates for the cost model) 304 
is contained in supplementary table S8. The parameter estimate for a particular factor affecting 305 
outcome is defined as the predicted increase in cost associated with a one unit increase in the value 306 
of that covariate.  307 
 308 
The predicted costs from these adjusted analyses are presented in Table 6 for a cohort of women with 309 
unexplained infertility – a group without an absolute barrier to conception who would be expected to 310 
have a reasonable chance of treatment independent pregnancy. The results show a cost increase 311 
associated with treatment which is higher among women in the lowest BMI group (across all age 312 
groups), and also highest among women aged 31-35 years, followed by women aged 36-40 years 313 
(compared to women in the youngest and oldest age groups).  314 
 315 
Additional cost per additional live birth associated with treatment 316 
A similar approach also assessed the predicted probability of live birth.  The live birth outcome model 317 
shows an uplift in the predicted probabilities of live birth with exposure to treatment, which is fairly 318 
consistent across age and BMI categories (~10%), except in the oldest age group where a slightly 319 
smaller increase in the probability of live birth is observed (see Table 6 and supplementary table S9). 320 
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Table 7 shows the difference in costs and the difference in the probability of live birth between treated 321 
and untreated couples with unexplained infertility across different BMI and age groups.  The ratio of 322 
these two quantities represents the additional cost per additional live birth associated with fertility 323 
treatment.  This ratio appears to be fairly consistent across the three youngest age groups.  However, 324 
it is consistently higher in women over the age of forty than it is for women in the other age groups 325 
(across all BMI categories).  For example, in women over 40 years of age with a BMI between 18.5 and 326 
25 kg/m2, the cost of an additional live birth with treatment was £32,785.52.  For a woman aged 36 to 327 
40 years with similar BMI, the cost of an additional live birth with treatment was £24,249.10.  A 328 
surprising finding is that this ratio tends to fall as BMI increases within all age groups. Similar findings 329 
were observed for the baseline risk predicted costs and live birth probabilities (see Supplementary 330 
Table S10). 331 
 332 
In both models the year of registration was statistically significant meaning that the costs and live birth 333 
outcomes changed over time, as one may expect.  To investigate this further we split the cohort into 334 
two time periods, i.e. 1998 to 2003 and 2004 to 2008, and refitted the models for each.  Generally, 335 
there was little difference between the effects of age, BMI and treatment in the two models 336 
(supplementary Tables S11 and S12).  For the cost model, the interaction between age and treatment 337 
status was not statistically significant for the earlier time period but was for the latter time period, 338 
with significantly less costs for treatment in women over 40 years.  339 
 340 
Multiple imputation of missing data (mainly BMI) did not appear to alter the magnitude and direction 341 
of the results substantially (supplementary tables S13 and S14) but the inclusion of 947 extra patients 342 
increased the statistical power resulting in narrower confidence intervals and more highly significant 343 
parameter estimates.  The predicted probabilities of live birth were generally slightly higher across all 344 
the age and BMI categories than those based on the analysis on the complete data (Supplementary 345 
Table S15).  The predicted costs from the analysis with imputed data were also slightly higher for all 346 
age and BMI categories apart from the lowest BMI category which had lower estimates. 347 
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 348 
Discussion 349 
Principal findings  350 
The results of this study show that within each age category, more women conceived spontaneously 351 
than as a result of fertility treatment. However, in women who received treatment, over 60% had a 352 
live birth either as a result of treatment (46.6%) or spontaneously at a later point in time (13.5%).  Of 353 
those who did not receive treatment, 42.3% had a live birth.  This explains why the increased predicted 354 
probability of live birth following treatment (versus no treatment) was higher across all age and BMI 355 
groups.  The size of this increase was fairly consistent across BMI and age, although it fell substantially 356 
in women over the age of 40 years.  357 
 358 
The cost of fertility investigations increased in line with BMI in normal BMI and overweight women, 359 
but was lower in women classified as obese (≥30kg/m2) and women >40 years. Women with normal 360 
BMI who had the highest overall conception rate incurred the highest costs of treatment as well as 361 
pregnancy and neonatal costs. In contrast, older women (> 40 years) and women in the high BMI 362 
groups were less likely to receive invasive investigations, such as laparscopy, and expensive 363 
treatments such as IVF.  Total costs were highest in women aged 30 years or less with a BMI less than 364 
18.5kg/m2.   The overall probability of live birth tended to decrease with increasing BMI within each 365 
age group. The ratio of the predicted increase in costs to the predicted increase in the probability of 366 
live birth (with treatment) was consequently highest for women in the oldest age group (>40 years), 367 
but tended to decrease with increasing BMI within each age group. 368 
 369 
Strengths and weaknesses of the study 370 
To our knowledge, this is the first study to explore the overall cost of providing fertility services to 371 
women of different ages and BMI groups, using direct health service costs and a relatively large sample 372 
of women. Whilst 29.5% of patients had missing BMI information, inclusion of data on these women 373 
using multiple imputation produced results which were similar to those where these were excluded.  374 
15 
 
As expected, several age and BMI group combinations were under-populated (as shown in Table 2) 375 
which may have introduced a level of uncertainty in the results for these groups.  However, as the 376 
tests of model fit and residual plots were satisfactory, the impact on the final quality of this analysis is 377 
likely to be small.  A key drawback of this study is the single centre retrospective design which made 378 
it impossible to adjust for clinician preference bias against planning investigations and treatment in 379 
older and heavier women which may have resulted in lower costs in these groups. However, due to 380 
the dominance of the non NHS private sector in fertility care and natural bias associated with under 381 
reporting of spontaneous pregnancy outcomes, it would be difficult to replicate this study in any other 382 
setting.  Aberdeen is unique in being a city with a single NHS fertility clinic (which is also the only 383 
provider of IVF in the region) and an NHS maternity unit, with no provision of either service in the 384 
private sector.   The live birth rates by age group in women who underwent IVF treatment at Aberdeen 385 
Fertility Centre in 2012 (33%, <35 years; 24%, 35-37 years; 19%, 38-39 years; 6%, >40 years) (see 386 
http://www.aberdeenfertility.org.uk/success-rates/)  were reasonably similar to the national average 387 
for 2011 (32.2%, <35 years; 27.4%, 35-37 years; 19.9%, 38-39 years; 13.4%, 40-42 years; 5.1%, 43-44 388 
years; 0.8%, >44 years) (Human Fertilisation and Embryology Authority, 2013).   389 
 390 
Strengths and weaknesses in relation to other studies 391 
A relatively high rate of spontaneous conception in a cohort of infertile couples has been 392 
demonstrated previously, especially for unexplained infertility (Brandes 2011, Collins 1995). This 393 
finding was confirmed on a much larger population by our study which is one of very few in the 394 
literature to be able to analyse longitudinal data on a population based cohort due to the unique 395 
nature of local fertility services. Most clinic based fertility studies have a natural reporting bias in terms 396 
of not being able to follow up women who conceive without treatment, while population based 397 
surveys based on self-completion of questionnaires can suffer from recall bias in terms of details of 398 
diagnosis and treatment.  399 
 400 
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This is the first study to provide a comprehensive assessment of total NHS costs for the diagnosis, 401 
treatment and follow-on care after pregnancy in women with infertility.  A previous study 402 
(Maheshwari et al, 2009) has investigated the impact of women’s BMI on IVF costs but was unable to 403 
capture the total costs of fertility management.  A subsequent study by Koning et al (2010) addressed 404 
the costs of fertility treatment in general for a hypothetical cohort of 1000 ovulatory and anovulatory 405 
women of different weight categories. That study did not account for other conditions, such as sperm 406 
dysfunction or tubal factor, and, in the absence of patient level data, relied on modelling techniques 407 
based on estimates published in the literature. Thus, it lacked precision and external validity due to its 408 
reliance on diverse sources of costs and outcomes reported in the literature over a long time period. 409 
In their model, Koning et al (2010) assumed that all overweight and obese women would follow the 410 
same pathway, although in actual fact, physician and patient choices can mean that this is not always 411 
the case.  Studies on direct health service costs of IVF treatment in women in different age groups 412 
(Maheshwari et al 2009, Suchartwatnachai et al 2000) showed that the cost of live birth increased 413 
with age and was considerably higher in women over 40 years. This was in agreement with our findings 414 
though Suchartwatnachai et al, (2000) used charges rather than direct health service costs.  Phillips et 415 
al (2000) has explored the costs of providing fertility treatment in women with different causes of 416 
infertility but none of the above mentioned studies has explored the costs of investigating infertile 417 
couples. 418 
 419 
Meaning of the results 420 
Higher costs in younger women with normal BMI reflect prevailing practice based on expert guidance 421 
(Balen and Anderson 2007). Unlike overweight and obese women in whom invasive tests or treatment 422 
are conditional on weight loss, younger and leaner women are more likely to be considered to be fit 423 
for full investigation and eligible for a greater number of treatments. As fertility is known to decline 424 
with age, older women are either likely to be offered rapid access to IVF or discouraged from active 425 
treatment if the prognosis is expected to be very poor. Thus, they are less likely to undergo expensive 426 
tests of tubal evaluation which are unlikely to contribute to clinical decision making, or incur the costs 427 
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of IVF when the outcome is expected to be poor. In contrast, younger women may be offered a variety 428 
of treatments, such as IUI, before moving onto more definitive treatment like IVF which is often 429 
perceived as a last resort.  430 
In terms of interpreting our results relating to costs and outcomes in older women, it is worth noting 431 
that women over 40 years were not eligible for NHS funded IVF during our study period. It is possible 432 
that our findings reflect the fact that only those deemed to have the best chance of conceiving (based 433 
on unobserved factors) decided to proceed with self-funded treatment. Younger women, who were 434 
more likely to receive NHS funded IVF had a better prognosis, but also a higher rate of multiples which 435 
contributed to increased combined pregnancy, delivery and neonatal costs.  The finding that the 436 
additional cost per live birth (associated with fertility treatment) decreased with BMI within age 437 
groups could be explained by the association between BMI and certain types of infertility. For 438 
example, in comparison to women with a normal BMI, fewer women with polycystic ovary syndrome, 439 
who tend to have a higher BMI, are likely to need IVF as they can often be treated successfully with 440 
less costly alternatives such as ovulation induction. 441 
 442 
Women with very low and very high BMI were younger at their first consultation, possibly because 443 
symptoms of anovulation, such as irregular or absent periods, prompted them to seek medical advice 444 
sooner.  445 
 446 
Within each age category, spontaneous conception rates were higher than those associated with 447 
fertility treatment. This supports the results of recent studies which have shown that young women 448 
with unexplained infertility have a higher spontaneous conception rate and early treatment does not 449 
appear to necessarily improve their chances (Steures et al, 2006, Bhattacharya et al, 2008, Brandes et 450 
al, 2011, Kamphuis et al, 2014) in comparison with expectant management.  451 
 452 
The additional cost per additional live birth with treatment was highest for women over 40 years of 453 
age, mainly due to the small increase in probability of treatment associated live-birth in this group.  454 
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This ratio showed a decreasing trend with rising BMI within all age groups, partly reflecting the fact 455 
that invasive and expensive investigations and treatments were more likely to be withheld in this 456 
group. Although local policy in keeping with British Fertility Society policy and practice guidelines 457 
(Balen and Anderson 2007) excluded women with BMI> 35kg/m2 from IVF treatment, some of them 458 
had spontaneous pregnancies. 459 
 460 
As changes in practice, clinical decision-making and resource use patterns are inevitable over the 11 461 
year study period, we fitted the models predicting costs and live birth separately for two time periods 462 
(1998 to 2003 and 2004 to 2008) as a post hoc analysis.  We found that for the first half of the study 463 
period there were no significant differences in total investigation and treatment costs across age 464 
groups in those treated and not treated.  However, during the second half, women aged 31 to 35 years 465 
who received treatment incurred significantly higher costs than those in other age groups whilst 466 
treated women over 40 years incurred significantly lower costs.  This suggests that early targeted 467 
delivery of IVF treatment to older women with a better prognosis may have become more frequent in 468 
more recent years. 469 
 470 
Implications for clinicians and policy makers 471 
The fact that treatment independent conception rates were higher than those associated with active 472 
treatment in the different age groups and predictably highest in younger women with unexplained 473 
infertility suggests that expectant management is a reasonable option in this group. However, it 474 
should be noted that the presence of other unmeasured patient and clinician factors may mean that 475 
for some of these patients, being treated is the better option.  This study demonstrates that our 476 
current approach of not over investigating women over 40 years of age and offering assisted 477 
reproduction where appropriate, still incurred the highest costs per additional live birth.  We advise 478 
further research to investigate cost-effectiveness of treatment in this group before making firm 479 
recommendations for clinicians and policy makers.  In women between the ages of 31 and 35 years in 480 
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whom treatment associated cost per additional live birth were highest, there may be scope to improve 481 
the targeting of treatment strategies. 482 
 483 
Unanswered questions and future research 484 
Further research is needed to explore more efficient pathways of investigating and treating fertility 485 
problems in younger women. This can be facilitated by developing more accurate prediction models 486 
for spontaneous pregnancy which would allow a more targeted approach towards identifying who 487 
would benefit from early investigation and treatment. As the additional benefit of treatment versus 488 
no treatment in women over 40 was modest, it is worth exploring the cost effectiveness of treating 489 
women in this age group. 490 
 491 
Conclusion 492 
Over half of all women with fertility problems conceive within 5 years of referral to secondary care 493 
and over a quarter conceive spontaneously. Women with normal BMI and those who are younger 494 
tend to incur higher NHS costs as they are more likely to receive a greater array of investigations and 495 
treatment, despite having a greater chance of treatment independent pregnancies. The additional 496 
cost per additional live birth associated with treatment rises with decreasing BMI in women of all age 497 
groups, suggesting that it may be possible to identify a more targeted approach to the provision of 498 
treatment in women with normal BMI. Future research should focus on efforts to develop better 499 
prediction models for spontaneous pregnancy and the assessment of more tailored treatment 500 
pathways based on such models.  501 
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